A Review of Suvorexant, Doxepin, Ramelteon, and Tasimelteon for the Treatment of Insomnia in Geriatric Patients.

Citation data:

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, ISSN: 0888-5109, Vol: 32, Issue: 3, Page: 156-160

Publication Year:
2017
Usage 88
Abstract Views 79
Link-outs 9
Captures 11
Readers 7
Exports-Saves 4
PMID:
28270270
DOI:
10.4140/tcp.n.2017.156
Author(s):
Edmonds, Chelsey, Swanoski, Michael
Publisher(s):
American Society of Consultant Pharmacists
Tags:
Medicine
review description
Geriatric patients often experience insomnia because of physiological and neurological changes that occur during the aging process. Use of benzodiazepines, nonbenzodiazepine hypnotics, and diphenhydramine for the treatment of insomnia pose an increased risk of cognitive impairment, falls, and fractures in this patient population. Therapeutic alternatives approved by the Food and Drug Administration include suvorexant, doxepin, ramelteon, and tasimelteon, which have shown efficacy and safety in various studies. This paper explores and outlines the available safety and efficacy data associated with these medications and reviews their potential place in therapy in treating insomnia in the geriatric population.

This review has 0 Wikipedia mention.